Cerity Partners
LRMR icon

Cerity Partners’s Larimar Therapeutics LRMR Stock Holding History

Cerity Partners’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$828K Buy
271,582
+23,670
+10% +$94K ﹤0.01% 2105
2026
Q1 		$1.12M Buy
247,912
+13,175
+6% +$52.7K ﹤0.01% 1796
2025
Q4 		$894K Sell
234,737
-4,409
-2% -$17.1K ﹤0.01% 1766
2025
Q3 		$772K Buy
239,146
+18,945
+9% +$71K ﹤0.01% 1729
2025
Q2 		$636K Buy
+220,201
New +$510K ﹤0.01% 1744

Other funds holding LRMR

BOCH
Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Cerity Partners's LRMR Position: Q2 2026 in Review

Cerity Partners increased its Larimar Therapeutics (LRMR) stake by 9.5% in Q2 2026, buying an estimated $94K and bringing the position to 271,582 shares worth $828K. The position accounts for ﹤0.01% of the portfolio, ranked #2105.

Cerity Partners first reported a position in LRMR in Q2 2025 and has held it in 5 quarters since. The position peaked at $1.12M in Q1 2026. 150 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

  • Cerity Partners held 271,582 shares of Larimar Therapeutics worth $828K as of Q2 2026.
  • Cerity Partners bought 23,670 Larimar Therapeutics shares in Q2 2026, an estimated $94K.
  • Larimar Therapeutics made up ﹤0.01% of Cerity Partners's portfolio in Q2 2026, its #2105 holding.
  • Cerity Partners first reported a position in Larimar Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Cerity Partners's Larimar Therapeutics position peaked at $1.12M in Q1 2026.
  • 150 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.